Busulfan

Form: Injection (IV), Oral Tablet

Strength: Injection: 6 mg/mL; Tablet: 2 mg

Reference Brands: US: Busulfex® (IV), Myleran® (oral); EU: Busilvex® (IV), Myleran® (tablet)

Category: Oncology Cancer Care

Busulfan, available in 6 mg/mL IV injection and 2 mg oral tablets, is a critical alkylating agent used in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT). Approved in both the US and EU under brands like Busulfex® and Busilvex®, it plays a key role in treating chronic myelogenous leukemia (CML) and other hematologic cancers. Manufactured under strict GMP conditions, Busulfan is supplied in sterile, ready-to-infuse formulations, making it ideal for oncology-focused B2B partnerships, licensing, and supply in regulated markets. Reliable sourcing of Busulfan is essential for transplant protocols in cancer care facilities.